A Phase 2 Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

PURPOSE: AZD6244 is a MEK1/2 inhibitor with significant preclinical activity in multiple myeloma (MM) cells. This phase 2 study used a two-stage Simon design to determine the AZD6244 response rate in patients with relapsed or refractory MM. EXPERIMENTAL DESIGN: AZD6244 (75 mg) was administered orall...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: Holkova, Beata, Zingone, Adriana, Kmieciak, Maciej, Bose, Prithviraj, Badros, Ashraf Z., Voorhees, Peter M., Baz, Rachid, Korde, Neha, Lin, Hui-Yi, Chen, Jin-Qiu, Herrmann, Michelle, Xi, Liqiang, Raffeld, Mark, Zhao, Xiuhua, Wan, Wen, Tombes, Mary Beth, Shrader, Ellen, Weir-Wiggins, Caryn, Sankala, Heidi, Hogan, Kevin T., Doyle, Austin, Annunziata, Christina M., Wellons, Martha, Roberts, John D., Sullivan, Daniel, Landgren, Ola, Grant, Steven
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2015
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4775365/
https://ncbi.nlm.nih.gov/pubmed/26446942
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-1076
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi